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============

COPD is the fifth leading cause of death worldwide. The epidemic of smoking has been the main contributing factor, responsible for 40--70% of the COPD cases.[@CIT0001] Other highly associated factors are age (over 65 years) and genetics.[@CIT0001] It has been found that white ancestry, exposure to air pollution or occupational exposure (dust, traffic exhaust fumes, sulphur dioxide), abnormal lung (childhood infection), male sex and a low socioeconomic status are weaker risk factors associated with COPD.[@CIT0001] Patients with COPD usually have other co-morbidities such as cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, lung cancer and diabetes.[@CIT0001],[@CIT0002] Additionally, psychiatric co-morbidities such as depression, anxiety and psychosis are common in COPD patients.[@CIT0002] The number of COPD cases is not expected to reduce in the future,[@CIT0001] and thus there is a need to find new ways of reducing the burden of COPD.

Physical activity involves the movement of the body caused by the muscles and shown to have health benefits.[@CIT0003] COPD decreases the capacity to perform physical activity.[@CIT0004] Physical activity is a significant predictor of survival of COPD patients,[@CIT0005] but a means to easily monitor and quantify physical activity in COPD patients has been lacking. Current wearable technology, also known as physical activity monitors or trackers, includes pedometers (providing steps over a period of time) and accelerometers (providing counts and/or estimates of energy expenditure). The most commonly used can be adjusted to the arm, waist, wrist, foot or thigh. Some locations (such as the arm) are more comfortable to the user and some others (such as the thigh) give more robust information. The relation between physical activity in COPD patients and their survival has been established,[@CIT0004],[@CIT0005] and the measurement of physical activity has thus the potential to be very valuable in routine clinical practice as a feedback and educational tool to improve the condition and survival.

Current wearable technology consists of a device fitted to the participant's body which detects and collects the data and requires access to a computer to retrieve the data. The reliability and validity of data collected depend solely on each individual device.[@CIT0006] Practical issues have been reported with physical activity trackers: some can be quite costly and uncomfortable or difficult to wear. Furthermore, the slow motion of patients with limited mobility, such as COPD patients, may not be detected by the sensors.[@CIT0006] Also, exercising while remaining static, such as arm movement only and pendulous abdomen movement, may not be measured. Or conversely, movements when it does not belong to the patient, such as the motion of a moving car, may be included.[@CIT0006],[@CIT0007] Problems related to adherence and proper usage have been noted by several studies on wearable devices monitoring physical activity (not limited to COPD studies).[@CIT0008]--[@CIT0011] These include an inconsistency between monitors and self-report questionnaires, likely due to the monitors, not the participants[@CIT0012] and a high signal-to-noise ratio.[@CIT0013]

Exacerbations of COPD leading to hospitalization are associated with a high risk of readmission.[@CIT0014] For hospitalized COPD patients, surrogate markers may be more appropriate instead of physical activity monitors.[@CIT0014] Physical frailty (gait speed \<0.8 m/s in the 4 m walk test) is a simple measure of physical performance and able to predict the risk of readmission in older patients who have been hospitalized due to COPD exacerbation.[@CIT0014]

While frailty is quite common in COPD patients, there is no evidence of an association between COPD and frailty.[@CIT0015] Thus, there is a need for an investigation into the effects of frailty on COPD patients, due to the large number affected.[@CIT0015] Also, it has recently been suggested that measuring frailty is important for risk stratification of COPD patients and the use of an upper-extremity function test in predicting adverse outcomes has been recommended.[@CIT0016]

The objective of our literature review was to assess the performance and effects of wearable technologies in COPD patients. We also evaluated any limitations for practical use and considered recommendations for best use of wearable technology in COPD patients.

Methods {#S0002}
=======

This literature review included randomized controlled trials (RCTs) and observational studies that used wearable technology to monitor physical activity in COPD patients. The studies had to be written in English and published in peer-reviewed journals. We excluded abstracts, protocols, pilot studies, duplicate articles, book chapters, studies not written in English, studies with the patient not being the main actor (eg, validating the technology was the goal of the study), studies that did not use wearable technology or used wearable technology for reasons other than monitoring physical activity (such as self-management of COPD), studies that did not include COPD patients or studies that only validated the technology and studies that evaluated the relation between physical activity and COPD (as this is already established on literature). The studies included in this review concerned COPD patients with severity according to the GOLD criteria ranging from mild to very severe. We also restricted the studies to those that evaluated wearable technology such as pedometers and accelerometers used for the purposes of monitoring physical activity. The primary outcomes that were evaluated in this review included step and activity counts or walk distance in miles as estimated by the monitor and the time spent in exercise. The secondary outcome included any technical and usability issues of the monitors experienced by COPD patients.

Results {#S0003}
=======

We identified nine RCTs and four observational studies from this literature search strategy. The duration of the studies varied from 48 hrs to 1 year. Only five of the studies used the monitor as part of the intervention, the others used the device to track physical activity only. The majority quantified physical activity into step counts, activity counts or walk distance. Other studies chose to present the duration (or amount) of time the patients spent in an exercise session.

Primary outcomes (monitor data) {#S0003-S2001}
-------------------------------

Step count: activity counts or walk distance in miles as found from the monitor

Studies that compared COPD patients with healthy controls found that physical activity in COPD patients was significantly less than in healthy people. There are interventions that increased the counts/distance in COPD patients.[@CIT0017],[@CIT0018] However, there are studies that found no difference between the intervention and control groups.[@CIT0013],[@CIT0019] Studies that have used the monitors as part of the intervention all found that the intervention group had improved more than the control group.[@CIT0020],[@CIT0021] 2. Time spent in exercise session

The monitors may help COPD patients in spending more time exercising: Hunter et al (2006) found that the COPD patients with monitors spent 103% more time compared with prescription only groups on each training session.[@CIT0022] An intervention managed to increase the time spent exercising,[@CIT0023] but another study did not achieve that result.[@CIT0024]

The primary and secondary outcomes for each of the 13 studies have been tabulated ([Table 1](#T0001){ref-type="table"}); secondary outcome noted technical or utility issues related to the wearable technology. Table 1Summary of the results reported on the use of wearable technology for monitoring physical activity in COPD patientsStudyPrimary outcomes:\
1) Step count, Activity counts or walk distance\
2) Time spent in exercise sessionSecondary outcome: Technical issues and monitor usabilitySingh et al, 2001[@CIT0025]1) Mean counts and total activity counts while brisk and slow walking in COPD group was significantly less than healthy group.Unable to assess upper body movementsBauldoff et al, 2002[@CIT0017]1) Cumulative distance walked by the intervention group was 19±16.7 miles compared to 15.4±8.0 miles for the control groupN/ASewell et al, 2005[@CIT0019]1) Significant statistical improvement in activity counts for both groups. There was an increase of 29.18% of activity monitor counts in the control group and 40.63% in the intervention groupN/AHunter et al, 2006[@CIT0022]1) Counts per minute of exercise sessions was 150% more than prescribed (range: 55--434%)Errors from a vibrating vehicle movement, poor between monitor reproducibilitySteele et al, 2008[@CIT0013]1) No statistically significant accelerometer activity difference between intervention and control at any time-pointHigh signal-to-noise ratio in sedentary populationMoy, 2009[@CIT0026]1) The overall mean steps per day for COPD patients was 2,026±1,783 (no comparison)Not accurate at low walking speeds, limited memory storage, cannot capture extreme activities or energy expenditureEffing et al, 2011[@CIT0018]1) Mean difference in steps between the two groups for the whole study period was 877 steps per day in favour of the intervention\
2) For total activity, the COPD group completed a mean time of 14,838±7 115 and healthy individuals completed 24,028±12 399.N/AKawagoshi, 2015[@CIT0023]2) The time spent walking in baseline and 1 year later changed more in the intervention group compared with the control group (intervention: 51.36±3.7, control: 12.3±25.5).N/AMendoza et al, 2015[@CIT0020]1) Intervention group had a progressive daily average step increase throughout the study. The intervention group had 3,080±3,254 daily steps, while the control group had 138.3±1,950 daily stepsN/AMoy, 2015[@CIT0021]1) Patients in the intervention group walked 779 more steps per day at 4 months. They increased significantly their mean daily step counts by 447 steps at 4 months, which was an increase of 13% from baseline. Patients in the control group, however, had a decrease of 346 daily step counts at 4 monthsN/AMoy et al, 2016[@CIT0027]1) No significant difference between the two groups (intervention and control) at 12 months and no significant change in their daily step count compared to baseline. The intervention group kept daily step counts higher than the baseline values throughout the studyN/AIwakura et al, 2016[@CIT0028]1) Significantly reduced number of daily steps in the COPD patients (mean =4,546, sd =2,992) compared to the healthy control (mean =8,713, SD =3,480)\
2) The time spent daily in moderate-to-vigorous physical activity from the COPD patients (mean =13.9, SD =14.0) was significantly less than the time spent from the healthy control (mean =27.4, SD =19.1)N/ANolan et al, 2017[@CIT0024]1) The median step-count target for the final week of the program in patients allocated at the intervention was 36% higher than the baseline step count\
2) The time spent in expending at least 3 metabolic equivalents (METs) did not differ between the two groups (intervention and control) at 3 different time-pointsComplaints about the location of the pedometer, not picking up all steps, adding more steps by shaking it, showing invalid or missing accelerometer data; a patient stopped using it because he/she was obsessed with the step-count target and wide data variability

Forest plots for effect in steps count {#S0003-S2002}
--------------------------------------

[Figure 1](#F0001){ref-type="fig"} shows the mean difference in the number of daily steps taken by COPD patients using a physical activity monitor compared to those without a control. This analysis was based on only two studies as other studies used different units.[@CIT0020],[@CIT0021] These two studies were found to be statistically heterogeneous with Higgin's I^2^=92%, which could be due to the monitors and the use of different algorithms and/or differences in their study designs. Using a random-effects model (recommended in case of heterogeneity), the mean improvement in daily steps with a physical activity monitor was 1,821.01 which was not statistically significant.Figure 1Forest plot of the mean difference in the number of daily steps in COPD patients using a physical activity monitor compared to those without a monitor as control.

Discussion {#S0004}
==========

This review focused on published studies that reported on the use of wearable technology for monitoring physical activity in COPD patients. Our literature search of electronic databases identified 13 studies. As the majority of studies did not use the same outcomes and units, we could compare only two studies which measured the effect that a physical activity monitor has on the number of steps taken daily by the participants. A random-effects model found that the mean difference in the number of steps was improved in those with monitors, but this was not statistically significant.

Our review has also identified that physical activity monitors will need to become more accurate (insensitive to low walking speeds, altering readings when shaken, memory storage problems, high signal-to-noise ratio) and their placement made more comfortable for the COPD user.[@CIT0013],[@CIT0024]--[@CIT0026] The effect of the monitor was assessed as an educational and motivational tool on the physical activity in COPD patients.[@CIT0020],[@CIT0024],[@CIT0026] More studies are needed to provide a robust analysis of the effectiveness and usability of these technologies. In order to be able to apply such a monitoring system more widely, there is a need for a platform where health care practitioners can monitor live data from the technology and health care professionals need to be trained to communicate better with patients. Some health care organizations recognize the necessity to use technology.[@CIT0029] However, a study showed that no strict guidelines have been set by the Department of Health and National Institute for Health and Care Excellence (NICE) for use of clinical technologies. As reported by Llewellyn et al, there is a need to evaluate technologies and an infrastructure to ensure diffusion more widely.[@CIT0030] Also, health care professionals will need to be trained in how to use and interpret these technologies. These issues will need to be addressed before these technologies can be used in the health care system.

More studies are needed to assess if a physical activity monitor can enhance physical activity in COPD patients. For now, there are not enough studies, and the few of them that use the monitor as an educational and motivational tool, are highly heterogeneous. Thus, no conclusion can be drawn about the effect that the monitor could have on the physical activity of COPD patients. We believe that such a relationship exists, and once it is established, the COPD patients can improve physical activity, and thus their survival.

This study has several limitations. Only a small number of studies were identified and these studies were highly heterogeneous, with only two comparable. The results cannot be conclusive and more RCTs are required before making any conclusions.

In conclusion, future research should focus on dealing with monitor issues (memory storage, noise-to-signal ratio, etc.) and more RCTs are required to find the effect of physical activity monitors as part of an exercise intervention for COPD patients. There is a need for more and better studies that estimate the costs and benefits of using these technologies and to develop a strategy that will make this kind of technology sustainable beyond the pilot stage.
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